Tinka Reports Updated PEA for Ayawilca Project: Highlights Potential to Become Top-10 Global Zinc Producer
After-Tax NPV8% of US$433M and IRR of 32% at $1.20/lb Zinc VANCOUVER, BC / ACCESSWIRE…
After-Tax NPV8% of US$433M and IRR of 32% at $1.20/lb Zinc VANCOUVER, BC / ACCESSWIRE…
VANCOUVER, BC / ACCESSWIRE / October 14, 2021 / Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FSE:9HB)…
LOS ANGELES, CA / ACCESSWIRE / October 14, 2021 / Novelty has always driven growth…
The CBDC-focused smart contract technology provider has partnered with a blockchain infrastructure network to make…
LYSAKER, NORWAY / ACCESSWIRE / October 14, 2021 / Norwegian maritime cleantech company TECO 2030…
STOCKHOLM, SE / ACCESSWIRE / October 14, 2021 / iZafe Group (STO:IZAFE-B) iZafe Group AB…
VANCOUVER, BC / ACCESSWIRE / October 14, 2021 / Blender Bites Ltd. (the “Company“, “Blender”…
CALGARY, AB / ACCESSWIRE / October 14, 2021 / Southern Energy Corp. (“Southern” or the…
Divestment of Narrabri thermal coal royalty for consideration of up to $36 million LONDON, UK…
The Inclusion and Diversity Score (IDS) aims to create a single, universal index which can…
Hawick, Scotland, 14 October 2021 – Emtelle, the leading global manufacturer of blown fibre cable,…
Fincons Group and MIA present the annual audio-visual industry event in hybrid format for the…
Industrial IoT in the Time of Covid-19 – uncovers plans to increase significantly IoT investment…
SAN JOSE, Calif. – October 14, 2021: A new partnership between Robin.io, Blue Arcus and…
The Proprietary Testkits Perform Identity Testing of Both THC and CBD in Cannabis Products VANCOUVER,…
Company announcement no. 10 A year of transition Statement by CEO Mauricio Graber: “Our performance…
This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected…
This Phase 3 clinical program will enroll over 1,300 people with diabetes and is expected…
New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with…
Short duration infusion of Gazyvaro® (obinutuzumab) is administered with a target infusion time of 90…